Patents by Inventor Michael C. Milone

Michael C. Milone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF CANCER USING CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20170335281
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of a cancer associated antigen as described herein. The invention also relates to chimeric antigen receptor (CAR) specific to a cancer associated antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a cancer associated antigen as described herein.
    Type: Application
    Filed: March 13, 2015
    Publication date: November 23, 2017
    Applicants: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Andreas Loew, Michael C. Milone, Daniel J. Powell, Jr., Yangbing Zhao
  • Treatment of cancer using a CD123 chimeric antigen receptor
    Patent number: 9815901
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
    Type: Grant
    Filed: August 19, 2015
    Date of Patent: November 14, 2017
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Saar Gill, David Glass, Saad Kenderian, Andreas Loew, Joan Mannick, Michael C. Milone, Leon Murphy, David L. Porter, Marco Ruella, Yongqiang Wang, Qilong Wu, Jiquan Zhang
  • Compositions and Methods for Treatment of Cancer
    Publication number: 20170283775
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Application
    Filed: November 17, 2016
    Publication date: October 5, 2017
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • COMBINATIONS OF LOW, IMMUNE ENHANCING, DOSES OF MTOR INHIBITORS AND CARS
    Publication number: 20170274014
    Abstract: The invention relates, in part, to a method of treating a subject comprising administering to the subject a low, immune enhancing of a mTOR inhibitor and an immune effector cell engineered to express a CAR.
    Type: Application
    Filed: July 21, 2014
    Publication date: September 28, 2017
    Inventors: Jennifer Brogdon, David Glass, Joan Mannick, Michael C. Milone, Leon Murphy
  • TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY
    Publication number: 20170260268
    Abstract: The present invention provides compositions and methods for regulating the specificity and activity of immune effector cells for use in immunotherapy. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “NKR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
    Type: Application
    Filed: September 17, 2015
    Publication date: September 14, 2017
    Inventors: Gregory BEATTY, Boris ENGELS, Neeraja IDAMAKANTI, Carl H JUNE, Andreas LOEW, Michael C. MILONE, Huijuan SONG, Enxiu WANG, Qilong WU
  • Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
    Patent number: 9745368
    Abstract: The present invention provides compositions and methods for regulating the specificity and activity of T cells. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “KIR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
    Type: Grant
    Filed: March 15, 2014
    Date of Patent: August 29, 2017
    Assignees: The Trustees of the University of Pennsylvania, Novartis AG
    Inventors: Michael C. Milone, Enxiu Wang
  • REGULATABLE CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20170081411
    Abstract: Provided are compositions and methods relating to regulatable chimeric antigen receptors (RCARs), natural killer cell receptor CARs (NKR-CARs), and regulatable NKR-CARs (RNKR-CARs), where the intracellular signaling or proliferation of the RCAR or RNKR-CAR can be controlled to optimize the use of an RCAR/NKR-CAR- or RNKR-CAR-expressing cell to provide an immune response. Cells can be engineered to express a RNKR-CAR or to express a RCAR and a NKR-CAR (e.g., inhibitory NKR-CAR). For example, a RCAR or RNKR-CAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR or RNKR-CAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.
    Type: Application
    Filed: March 13, 2015
    Publication date: March 23, 2017
    Applicants: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Boris Engels, Andreas Loew, Michael C. Milone, Li Zhou
  • COMPOSITIONS AND METHODS OF CHIMERIC AUTOANTIBODY RECEPTOR T CELLS
    Publication number: 20170051035
    Abstract: The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an autoantibody, vectors comprising the same, compositions comprising CAAR vectors packaged in viral particles, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified T cell expressing a CAAR (CAART) wherein the expressed CAAR comprises a desmoglein extracellular domain.
    Type: Application
    Filed: May 1, 2015
    Publication date: February 23, 2017
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Aimee S. PAYNE, Christoph T. ELLEBRECHT, Vijay BHOJ, Michael C. MILONE
  • Compositions and methods for treatment of cancer
    Patent number: 9540445
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: January 10, 2017
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Compositions and methods for treatment of cancer
    Patent number: 9518123
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: December 13, 2016
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Use of chimeric antigen receptor-modified T-cells to treat cancer
    Patent number: 9499629
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Grant
    Filed: December 9, 2011
    Date of Patent: November 22, 2016
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Compositions and methods for treatment of cancer
    Patent number: 9481728
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: November 1, 2016
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Compositions and methods for treatment of cancer
    Patent number: 9464140
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: October 11, 2016
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Compositions and Methods for Treatment of Cancer
    Publication number: 20160208012
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Application
    Filed: January 15, 2016
    Publication date: July 21, 2016
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Compositions and Methods for Treatment of Cancer
    Publication number: 20160194404
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Application
    Filed: January 15, 2016
    Publication date: July 7, 2016
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR -EXPRESSING CELLS
    Publication number: 20160185861
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), and compositions and reaction mixtures comprising the same.
    Type: Application
    Filed: December 28, 2015
    Publication date: June 30, 2016
    Inventors: Felipe Bedoya, Saba Ghassemi, Carl H. June, Bruce L. Levine, Jan J. Melenhorst, Michael C. Milone, Daniel J. Powell, JR., Zoe Zheng
  • Compositions and Methods for Treatment of Cancer
    Publication number: 20160159907
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Application
    Filed: December 30, 2015
    Publication date: June 9, 2016
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Compositions and Methods for Treatment of Cancer
    Publication number: 20160130355
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Application
    Filed: January 15, 2016
    Publication date: May 12, 2016
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Use of chimeric antigen receptor-modified T cells to treat cancer
    Patent number: 9328156
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: May 3, 2016
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • TREATMENT OF CANCER USING A CD33 CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20160096892
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.
    Type: Application
    Filed: July 21, 2015
    Publication date: April 7, 2016
    Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, NOVARTIS AG
    Inventors: Jennifer Brogdon, Hilmar Erhard Ebersbach, Saar Gill, David Glass, Thomas Huber, Julia Jascur, Saad Kenderian, Joan Mannick, Michael C. Milone, Leon Murphy, Celeste Richardson, Reshma Singh, Huijuan Song, Qilong Wu, Jiquan Zhang